- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Live Investor Briefing
Prescient Therapeutics (ASX: PTX)
Thursday 3rd September, 12pm (AEST)
Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.
In this session, James will discuss:
- The first-in-class cancer therapy PTX -100 – now in Phase 2a clinical trials.
- The potential to make Phase 2b a registration study2, with FDA Fast Track and Orphan Drug Designation secured.
- Why PTX is at a stage where it becomes attractive to large pharmaceutical companies.
This should be a fascinating session about why PTX-100 is one of the most advanced cancer therapies on the ASX1 and their plans for an accelerated commercial pathway after encouraging Phase 1b results3.
Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend the session
What is a 708 investor?By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal College of Pharmacy. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Dr Rebecca Lim
Senior Vice President of Scientific Affairs
Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.
Receive email updates
What is a 708 investor?By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.
- Based on public data
- Subject to regulatory approvals
- 100% clinical benefit rate and zero serious adverse events that were treatment related. CTCL subgroup, n=7 evaluable patients